Jason Drew Smith

All filings by Jason Drew Smith on record concern UroGen Pharma Ltd. The record holds 42 filings, for trades running from 17 May 2021 to 8 September 2026.

Both buying and selling appear: 1 purchase worth €32k, against 22 sales worth €719k. Taken together, the sales exceed the purchases by €687k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 19 option exercises. So far in 2026, the count stands at no purchases and 4 sales.

On 9 September 2026 came the latest disclosure, an option exercise in UroGen Pharma Ltd. The last purchase on record was published on 18 May 2021, which is 1,985 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.